Sold as Salutensin, Salutensin-Demi. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 15, 2026, FDA lists 6 applications for Hydroflumethiazide; Reserpine (sold as Salutensin, Salutensin-Demi), first approved Jun 20, 1960, with 0 new uses approved and 0 published complete response letters.
| Jun 20, 1960 | Salutensin, Salutensin-DemiNDA 12359 · New combination | Shire | 27 | Discontinued |
| Jan 11, 1985 | Reserpine And HydroflumethiazideANDA 88932 | Ivax Pharms | 0 | Discontinued |
| Sep 20, 1985 | Reserpine And HydroflumethiazideANDA 88907 | Par Pharm | 3 | Discontinued |
| — | Hydroflumethiazide And ReserpineANDA 88110 | Watson Labs | 0 | Discontinued |
| — | Hydroflumethiazide And ReserpineANDA 88127 | Watson Labs | 0 | Discontinued |
| — | Hydroflumethiazide And ReserpineANDA 88195 | Usl Pharma | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Par Pharm